Defective class II transactivator expression in a B lymphoma cell line

T. Prod'homme, B. Drénou, C. De Ruyffelaere, G. Barbieri, Wojciech Wiszniewski, C. Bastard, D. Charron, Catherine Alcaide-Loridan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Loss of MHC class II expression in B-cell lymphoma has been associated with a higher tumorigenicity resulting from lower titers of tumor-infiltrating lymphocytes. This report aims towards the identification of the molecular mechanism leading to defective MHC class II expression in a B-cell lymphoma cell line, Rec-1. We evidenced a coordinated alteration of HLA-D gene transcription, reminiscent of B lymphoblastoid cell lines from patients with MHC class II deficiency. Genetic complementation performed between these cell lines and the lymphoma cells indicated that Rec-1 is altered in the MHC2TA gene. MHC2TA encodes the class II transactivator (CIITA), the master regulator of HLA-D gene expression. However, the coding sequence of the Rec-1 CIITA transcript did not reveal any mutation that could hamper the activity of the encoded protein. In agreement with the genetic complementation analysis, we evidenced a highly residual CIITA protein expression in the Rec-1 cell line resulting from a transcriptional defect affecting MHC2TA expression. Anti-HLA-DR monoclonal antibody treatment has proved efficient in the destruction of B lymphoma cells. Our data indicate that the appearance of variants losing CIITA, and thereby HLA-DR, expression will require a thorough monitoring during such immunotherapy protocols.

Original languageEnglish (US)
Pages (from-to)832-840
Number of pages9
JournalLeukemia
Volume18
Issue number4
DOIs
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

Lymphoma
B-Cell Lymphoma
HLA-D Antigens
Cell Line
HLA-DR Antigens
Tumor-Infiltrating Lymphocytes
Immunotherapy
Genes
Proteins
Monoclonal Antibodies
Gene Expression
Mutation
MHC class II transactivator protein
Therapeutics

Keywords

  • Gene regulation
  • MHC
  • Transcription factor
  • Tumor immunity

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Prod'homme, T., Drénou, B., De Ruyffelaere, C., Barbieri, G., Wiszniewski, W., Bastard, C., ... Alcaide-Loridan, C. (2004). Defective class II transactivator expression in a B lymphoma cell line. Leukemia, 18(4), 832-840. https://doi.org/10.1038/sj.leu.2403315

Defective class II transactivator expression in a B lymphoma cell line. / Prod'homme, T.; Drénou, B.; De Ruyffelaere, C.; Barbieri, G.; Wiszniewski, Wojciech; Bastard, C.; Charron, D.; Alcaide-Loridan, Catherine.

In: Leukemia, Vol. 18, No. 4, 04.2004, p. 832-840.

Research output: Contribution to journalArticle

Prod'homme, T, Drénou, B, De Ruyffelaere, C, Barbieri, G, Wiszniewski, W, Bastard, C, Charron, D & Alcaide-Loridan, C 2004, 'Defective class II transactivator expression in a B lymphoma cell line', Leukemia, vol. 18, no. 4, pp. 832-840. https://doi.org/10.1038/sj.leu.2403315
Prod'homme T, Drénou B, De Ruyffelaere C, Barbieri G, Wiszniewski W, Bastard C et al. Defective class II transactivator expression in a B lymphoma cell line. Leukemia. 2004 Apr;18(4):832-840. https://doi.org/10.1038/sj.leu.2403315
Prod'homme, T. ; Drénou, B. ; De Ruyffelaere, C. ; Barbieri, G. ; Wiszniewski, Wojciech ; Bastard, C. ; Charron, D. ; Alcaide-Loridan, Catherine. / Defective class II transactivator expression in a B lymphoma cell line. In: Leukemia. 2004 ; Vol. 18, No. 4. pp. 832-840.
@article{4d32a85bf8ce49749aaab761aa0b293e,
title = "Defective class II transactivator expression in a B lymphoma cell line",
abstract = "Loss of MHC class II expression in B-cell lymphoma has been associated with a higher tumorigenicity resulting from lower titers of tumor-infiltrating lymphocytes. This report aims towards the identification of the molecular mechanism leading to defective MHC class II expression in a B-cell lymphoma cell line, Rec-1. We evidenced a coordinated alteration of HLA-D gene transcription, reminiscent of B lymphoblastoid cell lines from patients with MHC class II deficiency. Genetic complementation performed between these cell lines and the lymphoma cells indicated that Rec-1 is altered in the MHC2TA gene. MHC2TA encodes the class II transactivator (CIITA), the master regulator of HLA-D gene expression. However, the coding sequence of the Rec-1 CIITA transcript did not reveal any mutation that could hamper the activity of the encoded protein. In agreement with the genetic complementation analysis, we evidenced a highly residual CIITA protein expression in the Rec-1 cell line resulting from a transcriptional defect affecting MHC2TA expression. Anti-HLA-DR monoclonal antibody treatment has proved efficient in the destruction of B lymphoma cells. Our data indicate that the appearance of variants losing CIITA, and thereby HLA-DR, expression will require a thorough monitoring during such immunotherapy protocols.",
keywords = "Gene regulation, MHC, Transcription factor, Tumor immunity",
author = "T. Prod'homme and B. Dr{\'e}nou and {De Ruyffelaere}, C. and G. Barbieri and Wojciech Wiszniewski and C. Bastard and D. Charron and Catherine Alcaide-Loridan",
year = "2004",
month = "4",
doi = "10.1038/sj.leu.2403315",
language = "English (US)",
volume = "18",
pages = "832--840",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Defective class II transactivator expression in a B lymphoma cell line

AU - Prod'homme, T.

AU - Drénou, B.

AU - De Ruyffelaere, C.

AU - Barbieri, G.

AU - Wiszniewski, Wojciech

AU - Bastard, C.

AU - Charron, D.

AU - Alcaide-Loridan, Catherine

PY - 2004/4

Y1 - 2004/4

N2 - Loss of MHC class II expression in B-cell lymphoma has been associated with a higher tumorigenicity resulting from lower titers of tumor-infiltrating lymphocytes. This report aims towards the identification of the molecular mechanism leading to defective MHC class II expression in a B-cell lymphoma cell line, Rec-1. We evidenced a coordinated alteration of HLA-D gene transcription, reminiscent of B lymphoblastoid cell lines from patients with MHC class II deficiency. Genetic complementation performed between these cell lines and the lymphoma cells indicated that Rec-1 is altered in the MHC2TA gene. MHC2TA encodes the class II transactivator (CIITA), the master regulator of HLA-D gene expression. However, the coding sequence of the Rec-1 CIITA transcript did not reveal any mutation that could hamper the activity of the encoded protein. In agreement with the genetic complementation analysis, we evidenced a highly residual CIITA protein expression in the Rec-1 cell line resulting from a transcriptional defect affecting MHC2TA expression. Anti-HLA-DR monoclonal antibody treatment has proved efficient in the destruction of B lymphoma cells. Our data indicate that the appearance of variants losing CIITA, and thereby HLA-DR, expression will require a thorough monitoring during such immunotherapy protocols.

AB - Loss of MHC class II expression in B-cell lymphoma has been associated with a higher tumorigenicity resulting from lower titers of tumor-infiltrating lymphocytes. This report aims towards the identification of the molecular mechanism leading to defective MHC class II expression in a B-cell lymphoma cell line, Rec-1. We evidenced a coordinated alteration of HLA-D gene transcription, reminiscent of B lymphoblastoid cell lines from patients with MHC class II deficiency. Genetic complementation performed between these cell lines and the lymphoma cells indicated that Rec-1 is altered in the MHC2TA gene. MHC2TA encodes the class II transactivator (CIITA), the master regulator of HLA-D gene expression. However, the coding sequence of the Rec-1 CIITA transcript did not reveal any mutation that could hamper the activity of the encoded protein. In agreement with the genetic complementation analysis, we evidenced a highly residual CIITA protein expression in the Rec-1 cell line resulting from a transcriptional defect affecting MHC2TA expression. Anti-HLA-DR monoclonal antibody treatment has proved efficient in the destruction of B lymphoma cells. Our data indicate that the appearance of variants losing CIITA, and thereby HLA-DR, expression will require a thorough monitoring during such immunotherapy protocols.

KW - Gene regulation

KW - MHC

KW - Transcription factor

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=16544372644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544372644&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403315

DO - 10.1038/sj.leu.2403315

M3 - Article

C2 - 14973505

AN - SCOPUS:16544372644

VL - 18

SP - 832

EP - 840

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -